Tiziana Life Sciences Ltd (NASDAQ:TLSA) Short Interest Update

Tiziana Life Sciences Ltd (NASDAQ:TLSA) was the recipient of a large decline in short interest in December. As of December 15th, there was short interest totalling 170,100 shares, a decline of 18.3% from the November 30th total of 208,100 shares. Based on an average daily volume of 306,000 shares, the days-to-cover ratio is currently 0.6 days. Currently, 0.2% of the company’s stock are sold short.

Institutional Trading of Tiziana Life Sciences

An institutional investor recently raised its position in Tiziana Life Sciences stock. Zhang Financial LLC raised its position in Tiziana Life Sciences Ltd (NASDAQ:TLSA) by 24.2% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 69,387 shares of the company’s stock after purchasing an additional 13,500 shares during the period. Zhang Financial LLC owned 0.07% of Tiziana Life Sciences worth $67,000 as of its most recent filing with the Securities and Exchange Commission.

Tiziana Life Sciences Stock Performance

Shares of NASDAQ TLSA opened at $0.75 on Tuesday. The stock’s 50-day moving average is $0.93 and its two-hundred day moving average is $0.96. Tiziana Life Sciences has a 1-year low of $0.41 and a 1-year high of $1.74.

Tiziana Life Sciences Company Profile

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.